Martek gains strength in patent lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences announces Nov. 1 a judge in the U.S. District Court for the District of Delaware will enter a permanent injunction against Lonza, Ltd., Nutrinova Inc. and Nutrinova Nutrition Specialties & Food Ingredients GmbH in a patent infringement suit. In October, a court in Dusseldorf, Germany made a verbal order in favor of DHA marketer Martek Biosciences in its European patent infringement lawsuit against Lonza (1"The Tan Sheet" Oct. 29, 2007, In Brief). The suit involves Lonza's U.S. sale of fatty acid product Lonza DHA for use in functional foods and dietary supplements. The U.S. judge upheld the October 2006 jury verdict that Lonza infringed on Martek's three patents (2"The Tan Sheet" Oct. 30, 2006, p. 13). Columbia, Md.-based Martek says it expects Lonza to appeal the decision to the U.S. Court of Appeals for the Federal Circuit. "The permanent injunction will be in effect pending any appeal," the firm says...
You may also be interested in...
Martek wins patent infringement suit
A court in Dusseldorf, Germany, has made a verbal order in favor of DHA marketer Martek Biosciences in its European patent infringement lawsuit against Lonza, Celanese Ventures and Nutrinova Nutrition Specialties & Food Ingredients, Martek says Oct. 23. A three-judge panel ruled the defendants violated Martek's European DHA patent relating to microbial oils containing at least 35% DHA in functional foods and dietary supplements. A written order is expected within 30 days. The patent has been the subject of opposition proceedings in the EU since 1999, though a final resolution is expected in the second half of 2008. A U.S. federal district court in 2006 ruled Lonza's DHA activities infringed three U.S. Martek patents (1"The Tan Sheet" Oct. 30, 2006, p. 13)...
Martek Expects Growth With Restructuring Plan, Including Layoffs
Martek Biosciences continues to push its growth with a new restructuring plan that should make it leaner and meaner, according to an Oct. 26 release
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.